Skip to main content
OpenTrials
Completed

NCT Number: NCT01165268

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Profil Institute For Clinical Research, Inc.

Chula Vista, California, 91911, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for T2DM

  • Diagnosis of T2DM
  • Must be on one of the following therapies: diet therapy alone, diet plus a sulfonylurea, diet plus metformin, or diet plus sulfonylurea plus metformin
  • Subjects taking metformin, and/or sulfonylurea must be on a stable dose for at least 2 months prior to study drug administration
  • Must have a fasting plasma glucose concentration ≤ 200 mg/dl, and HbA1C ≤ 10%

Inclusion criteria

for healthy subjects:

  • Healthy subjects (as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations)

Inclusion criteria

for all subjects:

  • Subjects with (eGFR ≥ 60 and ≤ 160 mL/min/1.73m² and urinary albumin excretion < 300 mg/g creatinine)
  • Body Mass Index (BMI) of 18 to 38 kg/m²
  • Men and women, ages 18 to 65 years, inclusive

Exclusion criteria

for all subjects:

  • Subjects with Type 1 Diabetes or uncontrolled Type 2 Diabetes Mellitus
  • Subjects with T2DM with fasting plasma glucose > 200 mg/dL, healthy subjects with fasting plasma glucose > 105 mg/dL
  • Subjects with T2DM with HbA1C > 10.0%, healthy subjects with HbA1C > 6.8%

Treatment and study plan

Dapagliflozin

Drug

Tablets, Oral, 10 mg, Once daily, 7 days

Primary outcomes

  1. The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin

    Time frame: Before 7 days of oral administration of 10 mg of dapagliflozin

  2. The reduction in TmG after 7 days of oral administration of 10 mg of dapagliflozin

    Time frame: After 7 days of oral administration of 10 mg of dapagliflozin

Secondary outcomes

  1. Splay of the glucose titration curve

    Time frame: Before 7 days of oral administration of 10 mg of dapagliflozin

  2. Splay of the glucose titration curve

    Time frame: After 7 days of oral administration of 10 mg of dapagliflozin

  3. Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin

    Time frame: Study Day 7

  4. Pharmacokinetics (Cmin, Cmax, Tmax, and AUC (TAU)) of dapagliflozin

    Time frame: Study Day 8

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Collaborators

  • Bristol-Myers Squibb

Registry information

Official study title

Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jul 19, 2010
Registry last updated
Nov 17, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.